William J. Catalona, MD, explains how the approach of active surveillance in prostate cancer emerged alongside the advent of PSA screening.
William J. Catalona, MD, a professor of Urology at Northwestern University Feinberg School of Medicine, provides a history of the use of active surveillance for men with prostate cancer.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.